Small Molecule Protein Degraders
To order this 330+page report, which features 130+ figures and 145+ tables, please visit this link
The USD 3.6 billion (by 2030) financial opportunitywithin the target protein degradation market has been analyzed across thefollowing segments:
§ Typeof payment of licensing agreements
§ Upfrontpayments
§ Milestonepayments
§ Type of protein degrader
§ Degronimids
§ PROTACs
§ SARDs/ SERDs
§ SpecificBET and DUB inhibitors
§ Otherprotein degraders
§ Therapeutic area
§ Neurodegenerativedisorders
§ Oncologicaldisorders
§ Othertherapeutic areas
§ Routeof administration
§ Oral
§ Intravenous
§ Otherroutes
§ Keygeographical region
§ NorthAmerica
§ Europe
§ Asia-Pacific
The Targeted Protein Degradation Market: Focus on Therapeuticsand Technology Platforms (based on Degronimids, ENDTACs, EpichaperomeInhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs,Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUBInhibitors), 2020-2030 report features thefollowing companies, which we identified to be key players in this domain:
§ Arvinas
§ CaptorTherapeutics
§ Celgene
§ Genetech
§ KymeraTherapeutics
§ MissionTherapeutics
§ Progenra
§ RadiusHealth
§ SanofiGenzyme
§ Zenopharm
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Current Market Landscape
5. Company Profiles
6. Clinical Trial Analysis
7. KOL Analysis
8. Publication Analysis
9. Funding and Investment Analysis
10. Partnerships and Collaborations
11. MarketSizing and Opportunity Analysis
12. Executive Insights
13. Concluding Remarks
14. Appendix 1: Tabulated Data
15. Appendix 2: List of Companies andOrganizations
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
